Related references
Note: Only part of the references are listed.Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Pathways and mechanisms of venetoclax resistance
Prithviraj Bose et al.
LEUKEMIA & LYMPHOMA (2017)
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Avi Ashkenazi et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoidderived hematologic malignancies
Stephen E. Kurtz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Combined venetoclax and alvocidib in acute myeloid leukemia
James Bogenberger et al.
ONCOTARGET (2017)
Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia
Joshua J. Rusbuldt et al.
CANCER RESEARCH (2017)
Therapeutic targeting of acute myeloid leukemia stem cells
Daniel A. Pollyea et al.
BLOOD (2017)
Myelodysplastic syndromes: Contemporary review and how we treat
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
S. Jilg et al.
LEUKEMIA (2016)
Evolution of acute myelogenous leukemia stem cell properties after treatment and progression
Tzu-Chieh Ho et al.
BLOOD (2016)
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Xiaojia Niu et al.
CLINICAL CANCER RESEARCH (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma
Abdul Shukkur Ebrahim et al.
ONCOTARGET (2016)
Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia
Rongqing Pan et al.
BLOOD (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
James M. Bogenberger et al.
LEUKEMIA & LYMPHOMA (2015)
Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy
Claudia Bruedigam et al.
CELL STEM CELL (2014)
A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia
Martha L. Arellano et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
J. M. Bogenberger et al.
LEUKEMIA (2014)
A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3-or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia
Aaron D. Schimmer et al.
PLOS ONE (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
Twee Tsao et al.
ANNALS OF HEMATOLOGY (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
Simone M. Schoenwaelder et al.
BLOOD (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The Epidemiology of Myelodysplastic Syndromes
Mikkael A. Sekeres
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Aaron D. Schimmer et al.
CLINICAL CANCER RESEARCH (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia:: A Cancer and Leukemia Group B study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
G. Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Myelodysplastic syndromes: the complexity of stem-cell diseases
Seth J. Corey et al.
NATURE REVIEWS CANCER (2007)
Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML
Kensuke Kojima et al.
CELL CYCLE (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Mechanisms of disease - Cancer stem cells
Craig T. Jordan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse
Joseph Moore et al.
LEUKEMIA RESEARCH (2006)
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mechanisms of apoptosis through structural biology
N Yan et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY (2005)
Cell death: Critical control points
NN Danial et al.
CELL (2004)
Concepts of human leukemic development
JK Warner et al.
ONCOGENE (2004)
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
G Marcucci et al.
BLOOD (2003)
Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes
R Invernizzi et al.
LEUKEMIA & LYMPHOMA (2001)
Share Paper
